Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer

@article{Soyka2012ClinicalIO,
  title={Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer},
  author={Jan David Soyka and Marco A. Muster and Daniel T. Schmid and Burkhardt Seifert and Ulrike Schick and Raymond Miralbell and Sandra Jorcano and Kathrin Zaugg and H Seifert and Patrick Veit-Haibach and Klaus Strobel and Niklaus G. Schaefer and Daniela B. Husarik and Thomas F. Hany},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2012},
  volume={39},
  pages={936-943}
}
To investigate the clinical value of 18F-fluorocholine PET/CT (CH-PET/CT) in treatment decisions in patients with recurrent prostate cancer (rPCA). The study was a retrospective evaluation of 156 patients with rPCA and CH-PET/CT for restaging. Questionnaires for each examination were sent to the referring physicians 14–64 months after examination. Questions included information regarding initial extent of disease, curative first-line treatment, and the treatment plan before and after CH-PET/CT… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

The use of PET/CT in prostate cancer

Prostate Cancer and Prostatic Diseases • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…